Consistently, we reported that MALAT1 was upregulated in DN tissues and HG-treated HK-2 cells, and MALAT1 aggravated HG-induced renal tubular injury, further indicating that MALAT1 could be a therapeutic target for inhibiting DN progression. This evidence concerns the gene MALAT1 and liver dysplastic nodule.